PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33813027-10	2021	In addition, PA compounds downregulated the expression of VCAM-1, VE-cadherin, VEGFa, VEGFR2, TGF-beta, and IL-1beta, in inflamed ECs.	Protactinium	13-15	vascular endothelial growth factor A	Homo sapiens	79-84	
17543159-5	2007	RESULTS: The mean serum VEGF concentration in patients with active PA was 394.4 pg/ml (394 +/- 171.8), in patients with inactive PA 200.4 pg/ml (200.4 +/- 115.7), and in healthy subjects 214.3 pg/ml (214.3 +/- 162.1).	Protactinium	67-69	vascular endothelial growth factor A	Homo sapiens	24-28	
12949227-4	2003	Treating the vessels with VEGF induced a time- and concentration-dependent increase in Pa.	Protactinium	87-89	vascular endothelial growth factor A	Homo sapiens	26-30	
12115498-4	2002	In this study, we analyzed the effects of hypoxia, a common feature of solid tumors and a major drive to tumor angiogenesis, and of PA, a tryptophan catabolite produced under inflammatory conditions and endowed with several biologic properties, on the production of the angiogenic activator VEGF by advanced-stage human NB cell lines.	Protactinium	132-134	vascular endothelial growth factor A	Homo sapiens	291-295	
12115498-6	2002	VEGF upregulation by PA involved iron chelation because iron sulfate prevented this effect whereas the iron-chelating agent DFX induced VEGF production.	Protactinium	21-23	vascular endothelial growth factor A	Homo sapiens	0-4	
11813843-8	2001	We examined the expression of VEGF in the resected lung tissue of 4 patients with PA using immunohistochemistry.	Protactinium	82-84	vascular endothelial growth factor A	Homo sapiens	30-34	
9950855-4	1999	VEGF (10(-10) M) induced a two- to threefold increase in Pa, which was blocked by a monoclonal antibody directed against the VEGF receptor Flk-1/KDR, the phospholipase C (PLC) antagonist U-73122, or the protein kinase C (PKC) antagonist bisindolylmaleimide (BIM).	Protactinium	57-59	vascular endothelial growth factor A	Homo sapiens	0-4	
9950855-4	1999	VEGF (10(-10) M) induced a two- to threefold increase in Pa, which was blocked by a monoclonal antibody directed against the VEGF receptor Flk-1/KDR, the phospholipase C (PLC) antagonist U-73122, or the protein kinase C (PKC) antagonist bisindolylmaleimide (BIM).	Protactinium	57-59	vascular endothelial growth factor A	Homo sapiens	125-129	
18201521-8	2007	VEGF immunohistochemical staining combined with PAS staining showed that fibroblast-like cells in the network matrix were stained positively by VEGF and the septa of meshwork and extracellular matrices were stained positively by PAS.	Protactinium	229-232	vascular endothelial growth factor A	Homo sapiens	0-4	
12115498-9	2002	Moreover, Flp exerted similar inhibitory activity on VEGF induction by PA or DFX, suggesting that this compound targets an essential step in the signaling pathway that leads to VEGF expression.	Protactinium	71-73	vascular endothelial growth factor A	Homo sapiens	53-57	
33235044-3	2021	METHODS: VEGF release kinetics from PA gels were evaluated.	Protactinium	36-38	vascular endothelial growth factor A	Homo sapiens	9-13	
33235044-8	2021	RESULTS: VEGF was released from PA in a controlled-release manner.	Protactinium	32-34	vascular endothelial growth factor A	Homo sapiens	9-13	
33235044-13	2021	CONCLUSION: Our observations suggest that this bioengineered construct successfully acts as a chemo- attractant for circulating MSCs due to controlled release of VEGF from the PA gels.	Protactinium	176-178	vascular endothelial growth factor A	Homo sapiens	162-166	
24894645-7	2014	To confirm the therapeutic effect, the VEGF siRNA expressing plasmid was constructed and then delivered into cancer cells using PA-PEG1k-RGD.	Protactinium	128-130	vascular endothelial growth factor A	Homo sapiens	39-43	
32734173-6	2020	Real time polymerase chain reaction (RT-PCR) data showed that the DPSCs cultured in 235 Pa matrices demonstrated an increased expression of endothelial markers after 28 days, and the effect was enhanced upon VEGF incorporation.	Protactinium	88-90	vascular endothelial growth factor A	Homo sapiens	208-212	
32654099-5	2021	It was also confirmed that PA pre-treatment inhibited the expression of HIF-1alpha, thereby downregulating the hypoxia-associated gene/protein expressions such as GLUT-1, VEGF, ANG and FGF.	Protactinium	27-29	vascular endothelial growth factor A	Homo sapiens	171-175	
31460824-16	2020	Postprandial serum and PA +25OHCH caused increase of IL-33, MCP-1, ICAM-1, IL-32, VEGF, and CX3C-chemokine mRNA expression as compared with fasting serum (P < 0.05).	Protactinium	23-25	vascular endothelial growth factor A	Homo sapiens	82-86